Clinical Trial Update: Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma [Phase 2]

View source ↗

Summary

This Phase 2 randomized, double-blind study compares tremelimumab to placebo in unresectable malignant mesothelioma, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peritoneal Mesothelioma
• Pleural Mesothelioma

Drugs mentioned

• Tremelimumab (tremelimumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Unresectable Pleural or Peritoneal Malignant Mesothelioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2017-08-17